Patents by Inventor Shihe HOU

Shihe HOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin
    Patent number: 11944708
    Abstract: The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: April 2, 2024
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Shihe Hou
  • BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
    Publication number: 20230293449
    Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the status of one or more mTOR-activating aberration at one or more genes selected from the group consisting of TSC1, TSC2, RPS6, PTEN, TP53, RB1, ATRX, and FAT1.
    Type: Application
    Filed: December 19, 2022
    Publication date: September 21, 2023
    Inventors: Neil P. DESAI, Anita N. SCHMID, Shihe HOU, Andrew KWON
  • BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
    Publication number: 20230000844
    Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.
    Type: Application
    Filed: November 11, 2020
    Publication date: January 5, 2023
    Inventors: Neil P. DESAI, Anita N. SCHMID, Shihe HOU, Andrew KWON
  • SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES COMPRISING AN MTOR INHIBITOR AND ALBUMIN FOR TREATMENT OF DISEASES
    Publication number: 20220054404
    Abstract: The present invention provides compositions and devices for subcutaneously administering compositions comprising nanoparticles comprising an mTOR inhibitor and an albumin. The present application also provides methods of treating diseases by subcutaneously administering to an individual a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
    Type: Application
    Filed: March 18, 2020
    Publication date: February 24, 2022
    Inventors: Neil P. DESAI, Shihe HOU
  • BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
    Publication number: 20210137848
    Abstract: The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the status of one or more mTOR-activating aberration at one or more genes selected from the group consisting of TSC1, TSC2, RPS6, PTEN, TP53, RB1, ATRX, and FAT1.
    Type: Application
    Filed: December 2, 2020
    Publication date: May 13, 2021
    Inventors: Neil P. DESAI, Anita N. SCHMID, Shihe HOU, Andrew KWON
  • METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20210085621
    Abstract: The present applications provides methods of treating pulmonary hypertension (e.g., severe form of pulmonary arterial hypertension, e.g., WHO functional class III or IV pulmonary arterial hypertension) in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (e.g., rapamycin or a derivative thereof, e.g., rapamycin) and a earner protein (e.g., an albumin).
    Type: Application
    Filed: November 19, 2020
    Publication date: March 25, 2021
    Inventors: Neil P. DESAI, Shihe HOU
  • METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS VIA ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMIN
    Publication number: 20210000752
    Abstract: The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Inventors: Neil P. DESAI, Shihe HOU